RETRACTION article

Front. Cardiovasc. Med., 09 May 2023

Sec. Cardiovascular Biologics and Regenerative Medicine

Volume 10 - 2023 | https://doi.org/10.3389/fcvm.2023.1208579

Retraction: STK35 gene therapy attenuates endothelial dysfunction and improves cardiac function in diabetes

Article metrics

View details

2,2k

Views

886

Downloads

The journal retracts the 13 January 2022 article cited above.

Following publication, concerns were raised regarding the integrity of the images in the published figures. Image duplication concerns were identified in Figures 3D, 4E, 6. The authors failed to provide a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers’ policies. As a result, the data and conclusions of the article have been deemed unreliable and the article has been retracted.

This retraction was approved by the Chief Editors of Frontiers in Cardiovascular Medicine and the Chief Executive Editor of Frontiers. The authors have not responded to correspondence regarding this retraction.

Summary

Keywords

STK35, diabetes, cardiac function, Angiogenesis, Serine threonine kinase

Citation

Frontiers Editorial Office (2023) Retraction: STK35 gene therapy attenuates endothelial dysfunction and improves cardiac function in diabetes . Front. Cardiovasc. Med. 10:1208579. doi: 10.3389/fcvm.2023.1208579

Received

19 April 2023

Accepted

19 April 2023

Published

09 May 2023

Approved by

Ngan F Huang, Stanford University, United States

Volume

10 - 2023

Updates

Copyright

* Correspondence: Frontiers Editorial Office

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics